Loring Wolcott & Coolidge Fiduciary Advisors’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-330
| Closed | -$57K | – | 787 |
|
|
2021
Q3 | $57K | Sell |
330
-21
| -6% | -$2.75K | ﹤0.01% | 451 |
|
|
2021
Q2 | $44K | Buy |
+351
| New | +$44.3K | ﹤0.01% | 482 |
|
|
2021
Q1 | – | Sell |
-337
| Closed | -$43K | – | 766 |
|
|
2020
Q4 | $43K | Hold |
337
| – | – | ﹤0.01% | 445 |
|
|
2020
Q3 | $38K | Hold |
337
| – | – | ﹤0.01% | 424 |
|
|
2020
Q2 | $32K | Hold |
337
| – | – | ﹤0.01% | 415 |
|
|
2020
Q1 | $30K | Hold |
337
| – | – | ﹤0.01% | 422 |
|
|
2019
Q4 | $18K | Hold |
337
| – | – | ﹤0.01% | 548 |
|
|
2019
Q3 | $13K | Hold |
337
| – | – | ﹤0.01% | 553 |
|
|
2019
Q2 | $14K | Hold |
337
| – | – | ﹤0.01% | 544 |
|
|
2019
Q1 | $16K | Hold |
337
| – | – | ﹤0.01% | 537 |
|
|
2018
Q4 | $15K | Hold |
337
| – | – | ﹤0.01% | 543 |
|
|
2018
Q3 | $19K | Hold |
337
| – | – | ﹤0.01% | 500 |
|
|
2018
Q2 | $16K | Hold |
337
| – | – | ﹤0.01% | 519 |
|
|
2018
Q1 | $13K | Hold |
337
| – | – | ﹤0.01% | 572 |
|
|
2017
Q4 | $14K | Hold |
337
| – | – | ﹤0.01% | 550 |
|
|
2017
Q3 | $13K | Hold |
337
| – | – | ﹤0.01% | 546 |
|
|
2017
Q2 | $11K | Hold |
337
| – | – | ﹤0.01% | 543 |
|
|
2017
Q1 | $9K | Hold |
337
| – | – | ﹤0.01% | 559 |
|
|
2016
Q4 | $9K | Hold |
337
| – | – | ﹤0.01% | 543 |
|
|
2016
Q3 | $12K | Hold |
337
| – | – | ﹤0.01% | 534 |
|
|
2016
Q2 | $11K | Buy |
+337
| New | +$11K | ﹤0.01% | 539 |
|
Loring Wolcott & Coolidge Fiduciary Advisors's XLRN Position: Q4 2021 in Review
Loring Wolcott & Coolidge Fiduciary Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 330 shares — an estimated $57K sold.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in XLRN in Q2 2016 and held it in 21 quarters. The position peaked at $57K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Loring Wolcott & Coolidge Fiduciary Advisors sold 330 Acceleron Pharma shares in Q4 2021, an estimated $57K.
- Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Acceleron Pharma in Q2 2016 and held it in 21 quarters.
- Loring Wolcott & Coolidge Fiduciary Advisors's Acceleron Pharma position peaked at $57K in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.